Antithrombotische Therapie bei Lungenembolie

Abstract

The present article addresses clinical challenges associated with the choice of the anticoagulant agent, the definition of the duration of anticoagulant treatment and the assessment of the risk-to-benefit ratio of prolonged anticoagulation for patients with pulmonary embolism (PE).

Anticoagulation is performed with unfractionated heparin (UFH) in hemodynamically unstable patients and with low molecular weight heparins (LWMH) or fondaparinux in normotensive patients. In patients with high or intermediate clinical probability of pulmonary embolism, anticoagulation should be initiated without delay while awaiting the results of diagnostic tests. LMWH and fondaparinux are preferred over UFH in the initial anticoagulation of PE since they are associated with a lower risk of bleeding.

All patients with PE require therapeutic anticoagulation for at least three months. The current 2019 guidelines of the European Society of Cardiology (ESC) recommend that all eligible patients should be treated with a non-vitamin K antagonist oral anticoagulant (NOAC) in preference to a vitamin K antagonist (VKA). In patients with active cancer, Apixaban, Edoxaban and Rivaroxaban are effective alternatives to treatment with LMWH.

The decision on the duration of anticoagulation should consider both, the individual risk of PE recurrence and the individual risk of bleeding. The risk for recurrent PE after discontinuation of treatment is related to the features of the index PE event. While patients with a strong transient risk factor have a low risk of recurrence and anticoagulation can be discontinued after three months, patients with strong persistent risk factor (such as active cancer) have a high risk of recurrence and thus should receive anticoagulant treatment of indefinite duration. Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence.

Alle Patienten mit Lungenembolie benötigen eine therapeutische Antikoagulation für mindestens 3 Monate. Dieser Beitrag behandelt klinische Herausforderungen der Therapie: die Wahl des geeigneten Antikoagulanz, das Festlegen der Antikoagulationsdauer und die Abschätzung des Nutzen-Risiko-Verhältnisses. Besonders berücksichtigt werden dabei die Empfehlungen der kürzlich publizierten 2019-Leitlinie der European Society of Cardiology.

Schlüsselwörter

Lungenembolie - Antikoagulation - Nicht-Vitamin-K-abhängige orale Antikoagulanzien (NOAK) - Risikoabschätzung - Blutungsrisiko

Key words

pulmonary embolism - anticoagulation - non-vitamin K antagonist oral anticoagulants - risk assessment - bleeding risk

Publication History

Article published online:
15 July 2020

• Literatur

• 1 Konstantinides SV, Meyer G, Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2019;
• 2 Prucnal CK, Jansson PS, Deadmon E. et al. Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin. Acad Emerg Med 2019;
• 3 Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010;
• 4 van Es N, Coppens M, Schulman S. et al Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975 . doi:10.1182/blood-2014-04-571232
• 5 Pengo V, Denas G, Zoppellaro G. et al Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-1371 . doi:10.1182/blood-2018-04-848333
• 6 Bauersachs R, Langer F, Kalka C. et al Treatment of the antiphospholipid syndrome with direct oral anticoagulants Position statement of German societies. Vasa 2019; 48: 483-486 . doi:10.1024/0301-1526/a000815
• 7 Hokusai VTEI, Buller HR, Decousus H. et al Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415 . doi:10.1056/NEJMoa1306638
• 8 Trujillo-Santos J, Di Micco P, Dentali F. et al Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017; 117: 382-389 . doi:10.1160/TH16-07-0494
• 9 Agnelli G, Becattini C, Meyer G. et al Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 2020; 382: 1599-1607 . doi:10.1056/NEJMoa1915103
• 10 Raskob GE, van Es N, Verhamme P. et al Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378: 615-624 . doi:10.1056/NEJMoa1711948
• 11 Young AM, Marshall A, Thirlwall J. et al Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2018; 36: 2017-2023 . doi:10.1200/JCO.2018.78.8034
• 12 Khan F, Rahman A, Carrier M. et al Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366: l4363 . doi:10.1136/bmj.l4363
• 13 Couturaud F, Sanchez O, Pernod G. et al Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA 2015; 314: 31-40 . doi:10.1001/jama.2015.7046
• 14 Weitz JI, Lensing AWA, Prins MH. et al Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 2017; 376: 1211-1222 . doi:10.1056/NEJMoa1700518
• 15 Agnelli G, Buller HR, Cohen A. et al Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708 . doi:10.1056/NEJMoa1207541
• 16 Klok FA, Kooiman J, Huisman MV. et al Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 2015; 45: 201-210 . doi:10.1183/09031936.00040714
• 17 Gomez-Outes A, Lecumberri R, Suarez-Gea ML. et al Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. J Cardiovasc Pharmacol Ther 2015; 20: 490-500 . doi:10.1177/1074248415575154
• 18 Klok FA, Niemann C, Dellas C. et al Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis 2016; 41: 312-320 . doi:10.1007/s11239-015-1239-x
• 19 Klok FA, Hosel V, Clemens A. et al Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48: 1369-1376 . doi:10.1183/13993003.00280-2016
• 20 Steffel J, Verhamme P, Potpara TS. et al The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330-1393 . doi:10.1093/eurheartj/ehy136